Novel Pyrazole‐Based Benzofuran Derivatives as Anticancer Agents: Synthesis, Biological Evaluation, and Molecular Docking Investigations

Abstract

AbstractIn this work, the design, synthesis, and mechanistic studies of novel pyrazole‐based benzofuran derivatives 1–8 as anticancer agents were discussed. Cytotoxic potency of the title compounds was evaluated against the lung carcinoma A‐549, human‐derived colorectal adenocarcinoma HT‐29, breast adenocarcinoma MCF‐7 cells as well as mouse fibroblast 3T3‐L1 cells using XTT assay. Anticancer mechanistic studies were carried out with flow cytometry. XTT results revealed that all compounds exhibited dose‐dependent anti‐proliferative activity against the tested cancer cells, and especially compound 2 showed the strongest anti‐proliferative activity with an IC50 value of 7.31 μM and the highest selectivity (15.74) on MCF‐7 cells. Flow cytometry results confirmed that the cytotoxic power of compound 2 on MCF‐7 cells is closely related to mitochondrial membrane damage, caspase activation, and apoptosis orientation. Finally, molecular docking studies were applied to determine the interactions between compound 2 and caspase‐3 via in‐silico approaches. By molecular docking studies, free binding energy (ΔGBind), docking score, Glide score values as well as amino acid residues in the active binding site were determined. Consequently, these results constitute preliminary data for in vivo anticancer studies and have the potential as a chemotherapeutic agent.